Clinical Trial Insights

16 May 2025

SELLAS Life Sciences Initiates Pediatric AML Patient Dosing in Phase 2 SLS009 Trial

SELLAS Life Sciences announced the first pediatric patient has been dosed in its ongoing Phase 2 trial of SLS009 (tambiciclib) for relapsed/refractory...

16 May 2025

Voyager Therapeutics Announces Publication Demonstrating Novel AAV Capsid for Blood-Brain Barrier Transport

Voyager Therapeutics announced the publication of data in Molecular Therapy demonstrating the ability of alkaline phosphatase (ALPL) to transport a no...

15 May 2025

Soleno Therapeutics Announces Presentations on VYKAT XR for Prader-Willi Syndrome at PES 2025

Soleno Therapeutics announced poster presentations on its VYKAT XR (diazoxide choline) extended-release tablets at the Pediatric Endocrine Society (PE...

14 May 2025

First Participant Dosed in ACT-EARLY: A Primary Prevention Study for Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma announced the first participant has been dosed in ACT-EARLY, the first-ever primary prevention study for transthyretin amyloid cardio...

14 May 2025

Hemogenyx Pharmaceuticals Expands Pediatric R/R AML Trial for HG-CT-1 CAR-T Therapy

Hemogenyx Pharmaceuticals plc announced a protocol amendment to include pediatric patients with relapsed/refractory acute myeloid leukemia (R/R AML) i...

13 May 2025

Merck to Present Oncology Research at ASCO 2025

Merck announced that it will present new research on its oncology portfolio and pipeline at the 2025 ASCO Annual Meeting. Data will be showcased acro...

13 May 2025

Zomedica Launches Equine Asthma Clinical Registry Using PulseVet Shock Wave Therapy

Zomedica Corp. announced the launch of the Equine Asthma Clinical Registry, a program utilizing PulseVet® shock wave therapy as a non-invasive, drug-f...

12 May 2025

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic Dermatitis

AbCellera presented preclinical data on ABCL575, a half-life extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis. The da...

12 May 2025

Applied Therapeutics to Present Updated Data on Govorestat at PNS 2025 Meeting

Applied Therapeutics will present 12-month clinical data and new 18- and 24-month topline data from the INSPIRE Phase 3 trial of govorestat (AT-007) f...

12 May 2025

Indivior Advances Addex's GABAB PAM Program Through IND Enabling Studies

Indivior, partnering with Addex Therapeutics, successfully completed IND-enabling studies for a GABAB positive allosteric modulator (PAM) targeting su...

08 May 2025

Aspen Neuroscience Announces Positive 6-Month Results for Parkinson's Disease Cell Therapy

Aspen Neuroscience announced positive 6-month results from the ASPIRO Phase 1/2a trial of ANPD001, a personalized cell therapy for Parkinson's disease...

07 May 2025

ZIVO Bioscience Announces Positive Results in Avian Influenza Study

ZIVO Bioscience announced positive results from a University of Delaware study evaluating its algal-derived ingredients to mitigate avian influenza in...

06 May 2025

Nadunolimab Plus Pembrolizumab Shows Potential in Solid Tumors

Cantargia announced the publication of clinical trial results in Investigational New Drugs, showing the potential of nadunolimab combined with pembrol...

05 May 2025

Darnatein to Present Advances in Regenerative Biologics at BMP Conference

Darnatein, a subsidiary of OSR Holdings, will present data at the 14th International Bone Morphogenetic Protein (BMP) Conference on May 3, 2025. Dr. ...

05 May 2025

Endogenex Presents Positive 48-Week REGENT-1 Clinical Trial Results for Type 2 Diabetes Treatment

Endogenex announced positive 48-week results from its REGENT-1 clinical study at Digestive Disease Week 2025. The study evaluated the safety and effic...

05 May 2025

Nutshell Therapeutics Receives FDA Clearance for Phase 1 Trial of NTS071

Nutshell Therapeutics announced that the US FDA has cleared its Investigational New Drug (IND) application for NTS071, an oral, small molecule alloste...

01 May 2025

Bolt Biotherapeutics Presents Preclinical Data on Next-Generation Boltbody™ ISACs

Bolt Biotherapeutics announced preclinical results for its next-generation Boltbody™ ISACs targeting CEA and PD-L1 at the AACR Annual Meeting 2025. T...

01 May 2025

DecisionDx-Melanoma Test Outperforms Existing Methods in Identifying Low-Risk Melanoma Patients

A new study published in Cancer Diagnosis & Prognosis shows that Castle Biosciences' DecisionDx-Melanoma test surpasses both American Joint Committee ...

01 May 2025

Genocury Biotech's In Vivo CD19 CAR-T Therapy Shows Promise in Relapsed/Refractory DLBCL

Genocury Biotech announced positive clinical trial results for its novel in vivo CD19 CAR-T therapy treating relapsed/refractory diffuse large B-cell ...

01 May 2025

JediCare Medical Announces Successful First-in-Human Study of Novel Pulmonary Nodule Removal Device

JediCare Medical, in collaboration with West China Hospital, successfully completed a first-in-human feasibility study of their Pulmonary Nodule Grabb...

01 May 2025

Microglia Replacement Shows Promise in Treating Leukodystrophies

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania have developed a novel approach to treating leukodystroph...

01 May 2025

Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in Schizophrenia

Neurocrine Biosciences has initiated a Phase 3 registrational program for NBI-1117568, an oral muscarinic M4 selective receptor agonist, as a potentia...

01 May 2025

OBI Pharma's OBI-902 IND Application Cleared for Phase 1/2 Trial in Advanced Solid Tumors

OBI Pharma announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OBI-902, a Trop-2...

No date

Test Item